

LEGAL REPRESENTATIVE: Kirton & McConkie, Krieger, Michael F.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 114 and migraine/ab
L15 0 L14 AND MIGRAINE/AB

=> s 114 and migraine
L16 3 L14 AND MIGRAINE

=> s 114 and migraine/ab
L17 60 L14 AND MIGRAINE/AB

=> d ibib abs 60

L17 ANSWER 60 OF 60 USPAT2 on STN
ACCESSION NUMBER: 2002:27500 USPAT2 Full-text
TITLE: Method of treating migraines and pharmaceutical compositions
INVENTOR(S): Smitchieva, Kremena, Basking Ridge, NJ, United States
Reines, Scott A., New Hope, PA, United States
McKinney, Errol, Doylestown, PA, United States
Sandquiest, Eric J., Doylestown, PA, United States
Khanma, Deepak K., Furlong, PA, United States
Hargreaves, Richard, Terlings Park, UNITED KINGDOM
Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6384034	B2	20020507
APPLICATION INFO.:	US 2001-934823		20010822 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-429274, filed on 29 Oct 1999, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106605P	19981102 (60)
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Jarvis, William R. A.	
ASSISTANT EXAMINER:	Kim, Vickie	
LEGAL REPRESENTATIVE:	Yuro, Raynard, Billups, Richard C., Rose, David L.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	345	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A combination of a 5HT-sub.1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 59

L17 ANSWER 59 OF 60 USPAT2 on STN
ACCESSION NUMBER: 2006:175340 USPAT2 Full-text
TITLE: Benzodiazepine CGRP receptor antagonists
INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTARHH1626

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'USPATFULL, USPAT2' AT 13:08:14 ON 04 APR 2007
FILE 'USPATFULL' ENTERED AT 13:08:14 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 13:08:14 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	130.00	187.55

=> file uspatall

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	130.00	187.55

FILE 'USPATFULL' ENTERED AT 13:08:22 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:08:22 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 103628-46-2/rn
L14 286 103628-46-2/RN

=> d ibib 286

L14 ANSWER 286 OF 286 USPAT2 on STN
ACCESSION NUMBER: 2001:194589 USPAT2 Full-text
TITLE: Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances

INVENTOR(S):

Zhang, Jie, Salt Lake City, UT, UNITED STATES
Hull, Wade, Taylorsville, UT, UNITED STATES
Rigby, Larry, Salt Lake City, UT, UNITED STATES
Stanley, Theodore, Salt Lake City, UT, UNITED STATES
Zars, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6955819	B2	20051018
APPLICATION INFO.:	US 2001-796250		20010228 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-545591, filed on 7 Apr 2000, PENDING Division of Ser. No. US 1998-162890, filed on 29 Sep 1998, Pat. No. US 6245347		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-185913P	20000229 (60)
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dodson, Shelley A.	
ASSISTANT EXAMINER:	George, Konata M.	

L14 ANSWER 286 OF 286 USPAT2 on STN
ACCESSION NUMBER: 2001:194589 USPAT2 Full-text
TITLE: Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances

INVENTOR(S): Zhang, Jie, Salt Lake City, UT, UNITED STATES
Hull, Wade, Taylorsville, UT, UNITED STATES
Rigby, Larry, Salt Lake City, UT, UNITED STATES
Stanley, Theodore, Salt Lake City, UT, UNITED STATES
Zars, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)

PATENT ASSIGNEE(S):

PATENT ASSIGNEE(S) : Merck & Co, Inc., Rahway, NJ, UNITED STATES (U.S. corporation)

PATENT INFORMATION: US 7196079 B2 20070327
WO 200500807 20050106
APPLICATION INFO.: US 2004-562298 (10)
WO 2004-US20206 20040624
20051222 PCT 371 date

PRIORITY INFORMATION: US 2003-482674P 20030626 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Rose, David L., Rubin, David
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of Formula I:

##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 58

L17 ANSWER 58 OF 60 USPATFULL on STN
ACCESSION NUMBER: 91:62807 USPATFULL Full-text
TITLE: Indole derivative
INVENTOR(S): Oxford, Alexander W., Royston, England
PATENT ASSIGNEE(S): Glaxo Group Limited, England (non-U.S. corporation)

PATENT INFORMATION: US 5037845 19910806
APPLICATION INFO.: US 1989-317682 19890301 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1987-82666, filed on 7 Aug 1987, now abandoned which is a continuation of Ser. No. US 1985-761392, filed on 1 Aug 1985, now abandoned

PATENT INFORMATION: GB 1984-19575 19840801
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ceperley, Mary E.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1, 5
LINE COUNT: 1276

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula (I) ##STR1## and its physiologically acceptable salts and solvates are described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature in particular migraine.

The compound (I) may be prepared, for example, by cyclizing a compound of formula (II).
##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>
=> d ibib abs 57

L17 ANSWER 57 OF 60 USPATFULL on STN
ACCESSION NUMBER: 1998:45217 USPATFULL Full-text
TITLE: Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
INVENTOR(S): Cohen, Marlene L., Carmel, IN, United States
Johnson, Kirk W., Indianapolis, IN, United States
Phebus, Lee A., Fountaintown, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PATENT INFORMATION: US 5744482 19980428
APPLICATION INFO.: US 1994-318391 19941005 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Gaylo, Paul J., Boone, David E.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1
LINE COUNT: 1252

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 56

L17 ANSWER 56 OF 60 USPATFULL on STN
ACCESSION NUMBER: 1999:1249 USPATFULL Full-text
TITLE: Method of treatment of migraine
INVENTOR(S): Peyman, Gholam A., 202 Gravier, Suite B, New Orleans, LA, United States 70112-2234

PATENT INFORMATION: US 5855907 19990105
APPLICATION INFO.: US 1997-828144 19970324 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Azpuru, Carlos A.
LEGAL REPRESENTATIVE: Dechert Price & Rhoads
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 450

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to, among other things, methods of treatment of migraine headache in humans with reduced side effects by the topical administration of a migraine -ameliorating effective amount of an opioid, singly, or in combination with other

pharmacological agents, including vasoconstrictors, antiinflammatory agents, antimicrobial agents, decongestants and non-opioid migraine drugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 117 and crystalline
L18 11 L17 AND CRYSTALLINE

=> d ibb abs tot

L18 ANSWER 1 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2007:64617 USPATFULL Full-text
TITLE: Preemptive prophylaxis of migraine
INVENTOR(S): Cady, Roger K., 631 Riverview Rd., Ozark, MO, UNITED STATES 65721
Guterman, Donna Lee, c/o Glaxo Wellcome Inc. Five Moore Dr., P.O. Box 13398, Research Triangle Park, NC, UNITED STATES 27709-3398
O'Quinn, Stephen Venson, c/o Glaxo Wellcome Inc. Five Moore Dr., P.O. Box 13398, Research Triangle Park, NC, UNITED STATES 27709-3398

PATENT INFORMATION: US 7189753 B1 20070313
APPLICATION INFO.: US 2000-575277 20000522 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1999-US9414, filed on 29 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-185310, filed on 3 Nov 1998, Pat. No. US 6086092

NUMBER KIND DATE

PRIORITY INFORMATION: US 1997-64879P 19971106 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kim, Vickie
LEGAL REPRESENTATIVE: Husch & Eppenberger LLC, Rusche, H. Frederick
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of preventing the headache phase of migraine in a human comprises administration of a 5HT.sub.1 receptor agonist or administration of an over-the-counter or nonprescription drug to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the 5HT.sub.1 agonist or over-the-counter or nonprescription drug. There is disclosed a preemptive prophylaxis migraine method using the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task; and interpreting the results as a percent of baseline indicator of need for prophylaxis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 2 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:302361 USPATFULL Full-text
TITLE: Substituted indole compounds having NOS inhibitory activity

INVENTOR(S): Maddaford, Shawn, Mississauga, CANADA
Ramnauth, Jallal, Brampton, CANADA
Rakhit, Suman, Mississauga, CANADA
Patman, Joanne, Mississauga, CANADA
Renton, Paul, Toronto, CANADA

Annedi, Subhash C., Mississauga, CANADA

NUMBER KIND DATE

PATENT INFORMATION: US 2006258721 A1 20061116
APPLICATION INFO.: US 2006-404267 A1 20060413 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2005-670856P 20050413 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 6673

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:273924 USPATFULL Full-text
TITLE: Delivery of compounds for the treatment of headache through an inhalation route

INVENTOR(S): Hale, Ron L., Woodside, CA, UNITED STATES
Rabinowitz, Joshua D., Princeton, NJ, UNITED STATES
Solias, Dennis W., San Francisco, CA, UNITED STATES
Zaffaroni, Alejandro C., Achertson, CA, UNITED STATES
Alexza Pharmaceuticals, Inc., Palo Alto, CA, UNITED STATES (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2006233717 A1 20061019
APPLICATION INFO.: US 2006-385992 A1 20060321 (11)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-792012, filed on 3 Mar 2004, GRANTED, Pat. No. US 7018621
Continuation of Ser. No. US 2002-155621, filed on 22 May 2002, GRANTED, Pat. No. US 6759029
Continuation-in-part of Ser. No. US 2004-766574, filed on 27 Jan 2004, GRANTED, Pat. No. US 7045118
Continuation of Ser. No. US 2003-735496, filed on 12 Dec 2003, GRANTED, Pat. No. US 7005121
Ser. No. US 2002-154594, filed on 23 May 2002, GRANTED, Pat. No. US 6740309
Continuation-in-part of Ser. No. US 2004-792239, filed on 3 Mar 2004, GRANTED, Pat. No. US 7014840
Continuation of Ser. No. US 2002-155705, filed on 22 May 2002, GRANTED, Pat. No. US 6805854

NUMBER DATE

PRIORITY INFORMATION: US 2001-294203P 20010524 (60)
US 2001-317479P 20010905 (60)
US 2001-332280P 20011121 (60)
US 2001-336218P 20011030 (60)
US 2001-294203P 20010524 (60)
US 2001-317479P 20010905 (60)

FILE SEGMENT: 20010524 (60)
US 2001-294203P
UTILITY
FILE SEGMENT: 20010905 (60)
US 2001-317479P
APPLICATION
LEGAL REPRESENTATIVE: SWANSON & BRATTSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129, US
INVENTOR(S):
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 11 USPATFULL ON STN
ACCESSION NUMBER: 2006:175340 USPATFULL Full-text
TITLE: Benzodiazepine cgpr receptor antagonists
INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES

NUMBER	KIND	DATE
US 2006:148790	A1	20060706
US 7196079	B2	20070327
US 2004-562298	A1	20040624 (10)
WO 2004-US20206		20040624
		20051222 PCT 371 date

PATENT INFORMATION: US 2003-60482674 20030626

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MERCK AND CO., INC. P O BOX 2000, RAHWAY, NJ, 07065-0907, US

NUMBER OF CLAIMS: 61

EXEMPLARY CLAIM: 1

LINE COUNT: 2196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of Formula I: ##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 5 OF 11 USPATFULL ON STN

ACCESSION NUMBER: 2006:159976 USPATFULL Full-text

TITLE: Benzodiazepine cgpr receptor antagonists

INVENTOR(S): Burgey, Christopher S., UNITED STATES

NUMBER	KIND	DATE
US 2006:135511	A1	20060622
US 2004-562297	A1	20040624 (10)
WO 2004-US20209		20040624
		20051222 PCT 371 date

PATENT INFORMATION: US 2006:135511

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Burgey, Christopher S., UNITED STATES

NUMBER OF CLAIMS: 61

EXEMPLARY CLAIM: 1

LINE COUNT: 2196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of Formula I: ##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

FILE SEGMENT: 20010524 (60)
US 2001-294203P
UTILITY
FILE SEGMENT: 20010905 (60)
US 2001-317479P
APPLICATION
LEGAL REPRESENTATIVE: SWANSON & BRATTSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129, US
INVENTOR(S):
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 11 USPATFULL ON STN
ACCESSION NUMBER: 2006:175340 USPATFULL Full-text
TITLE: Benzodiazepine cgpr receptor antagonists
INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES

NUMBER	KIND	DATE
US 2006:148790	A1	20060706
US 7196079	B2	20070327
US 2004-562298	A1	20040624 (10)
WO 2004-US20206		20040624
		20051222 PCT 371 date

PATENT INFORMATION: US 2003-60482674 20030626

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MERCK AND CO., INC. P O BOX 2000, RAHWAY, NJ, 07065-0907, US

NUMBER OF CLAIMS: 61

EXEMPLARY CLAIM: 1

LINE COUNT: 2196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of Formula I: ##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 5 OF 11 USPATFULL ON STN

ACCESSION NUMBER: 2006:159976 USPATFULL Full-text

TITLE: Benzodiazepine cgpr receptor antagonists

INVENTOR(S): Burgey, Christopher S., UNITED STATES

NUMBER	KIND	DATE
US 2006:135511	A1	20060622
US 2004-562297	A1	20040624 (10)
WO 2004-US20209		20040624
		20051222 PCT 371 date

PATENT INFORMATION: US 2006:135511

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Burgey, Christopher S., UNITED STATES

NUMBER OF CLAIMS: 61

EXEMPLARY CLAIM: 1

LINE COUNT: 2196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of Formula I: ##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

FILE SEGMENT: 20010524 (60)
US 2001-294203P
UTILITY
FILE SEGMENT: 20010905 (60)
US 2001-317479P
APPLICATION
LEGAL REPRESENTATIVE: SWANSON & BRATTSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129, US
INVENTOR(S):
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 11 USPATFULL ON STN
ACCESSION NUMBER: 2006:175340 USPATFULL Full-text
TITLE: Benzodiazepine cgpr receptor antagonists
INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES

NUMBER	KIND	DATE
US 2006:148790	A1	20060706
US 7196079	B2	20070327
US 2004-562298	A1	20040624 (10)
WO 2004-US20206		20040624
		20051222 PCT 371 date

PATENT INFORMATION: US 2003-60482674 20030626

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MERCK AND CO., INC. P O BOX 2000, RAHWAY, NJ, 07065-0907, US

NUMBER OF CLAIMS: 61

EXEMPLARY CLAIM: 1

LINE COUNT: 2196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of Formula I: ##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 5 OF 11 USPATFULL ON STN

ACCESSION NUMBER: 2006:159976 USPATFULL Full-text

TITLE: Benzodiazepine cgpr receptor antagonists

INVENTOR(S): Burgey, Christopher S., UNITED STATES

NUMBER	KIND	DATE
US 2006:135511	A1	20060622
US 2004-562297	A1	20040624 (10)
WO 2004-US20209		20040624
		20051222 PCT 371 date

PATENT INFORMATION: US 2006:135511

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Burgey, Christopher S., UNITED STATES

NUMBER OF CLAIMS: 61

EXEMPLARY CLAIM: 1

LINE COUNT: 2196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of Formula I: ##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Sleeth, Timothy, Blue Bell, PA, UNITED STATES

INVENTOR(S):
NUMBER KIND DATE
US 2004204341 A1 20041014
US 2003-479923 A1 20031205 (10)
WO 2002-US21069

PATENT INFORMATION:
APPLICATION INFO.:
US 2001-297672P 20010612 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 5753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses a method for treating or preventing migraines in a mammalian patient in need of such treatment or prevention comprising administering to said patient an NR2B receptor antagonist in an amount that is effective to treat or prevent migraines. The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist or a 5HT_{1B/1D} agonist for the treatment or prevention of migraines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 8 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2004-203899 USPATFULL Full-text
TITLE: Rapid absorption selective 5-HT₁ agonist formulations
INVENTOR(S): Mezaache, Naima, McLean, VA, UNITED STATES
Mezaache, Djelila, Laurel, MD, UNITED STATES
Frisbee, Steve, Reston, VA, UNITED STATES
Maes, Paul, Toronto, CANADA

PATENT INFORMATION:
APPLICATION INFO.:
US 2004162333 A1 20040819
US 2004-779784 A1 20040218 (10)

PRIORITY INFORMATION:
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300
NUMBER OF CLAIMS: 135
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 2725

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides for a rapid absorption pharmaceutical composition comprising an effective amount of at least one selective 5-HT₁ agonist, at least one spheronization aid and at least one solubility enhancer. The composition of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 9 OF 11 USPATFULL on STN
ACCESSION NUMBER: 1998-45217 USPATFULL Full-text
TITLE: Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of

migraine

INVENTOR(S): Cohen, Marlene L., Carmel, IN, United States
Johnson, Kirk W., Indianapolis, IN, United States
Phebus, Lee A., Fountaintown, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

NUMBER KIND DATE
US 5744482 19980428
US 1994-318391 19941005 (8)
APPLICATION INFO.: Utility
DOCUMENT TYPE: Granted
FILE SEGMENT: Spivack, Phyllis G.
PRIMARY EXAMINER: Gaylo, Paul J., Boone, David E.
LEGAL REPRESENTATIVE: 5
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1252

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 10 OF 11 USPATFULL on STN
ACCESSION NUMBER: 91-62807 USPATFULL Full-text
TITLE: Indole derivative
INVENTOR(S): Oxford, Alexander W., Royston, England
PATENT ASSIGNEE(S): Glaxo Group Limited, England (non-U.S. corporation)

NUMBER KIND DATE
US 5037845 19910806
US 1989-317682 19890301 (7)
APPLICATION INFO.: Continuation of Ser. No. US 1987-82666, filed on 7 Aug 1987, now abandoned which is a continuation of Ser. No. US 1985-761392, filed on 1 Aug 1985, now abandoned
RELATED APPLN. INFO.:

PRIORITY INFORMATION:
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ceperley, Mary E.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1, 5
LINE COUNT: 1276

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula (I) #STR1# and its physiologically acceptable salts and solvates are described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature in particular migraine.

The compound (I) may be prepared, for example, by cyclizing a compound of formula (II) #STR2#

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 11 OF 11 USPAT2 on STN
ACCESSION NUMBER: 2006-175340 USPAT2 Full-text
TITLE: Benzodiazepine CGRP receptor antagonists

INVENTOR(S) : Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES
PATENT ASSIGNEE(S) : Merck & Co., Inc., Rahway, NJ, UNITED STATES (U.S. corporation)

PATENT INFORMATION: NUMBER KIND DATE
US 7196079 B2 20070327
WO 2005000807 20050106
APPLICATION INFO.: US 2004-562298 20040624 (10)
WO 2004-US20206 20040624
20051222 PCT 371 date

PRIORITY INFORMATION: NUMBER DATE
US 2003-482674P 20030626 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Rose, David L., Rubin, David
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1945
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of Formula I:

##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> log hold
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY 88.86 SESSION 276.41
FULL ESTIMATED COST

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:30:56 ON 04 APR 2007

CN Imigrane
 CN Imiject
 CN Imitrex
 CN Megrelan
 CN Migragesin
 CN Sumatriptan succinate
 CN Sumitrex
 MF C14 H21 N3 O2 S . C4 H6 O4
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CERB, CHEMCATS, CHEMLIST, CIN, CSCEM, EMBASE, IMSCSEARCH, IMPSPATENTS, IMSRESEARCH, IPA, MRCK*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

CM 1
 CRN 103628-46-2
 CMF C14 H21 N3 O2 S



CM 2
 CRN 110-15-6
 CMF C4 H6 O4

HO2C-CH2-CH2-CO2H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

157 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 160 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file uspatall
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 SINCE FILE ENTRY
 TOTAL SESSION
 7.35 57.55

FILE 'USPATFULL' ENTERED AT 10:45:58 ON 04 APR 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
 FILE 'USPAT2' ENTERED AT 10:45:58 ON 04 APR 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l10
 L11 106 L10

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTARHH1626

PASSWORD:
 ***** RECONNECTED TO STN INTERNATIONAL *****
 SESSION RESUMED IN FILE 'REGISTRY' AT 10:45:17 ON 04 APR 2007
 FILE 'REGISTRY' ENTERED AT 10:45:17 ON 04 APR 2007
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 SINCE FILE ENTRY
 TOTAL SESSION
 22.50 50.20

=> file reg
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 SINCE FILE ENTRY
 TOTAL SESSION
 22.50 50.20

FILE 'REGISTRY' ENTERED AT 10:45:22 ON 04 APR 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 APR 2007 HIGHEST RN 929074-02-2
 DICTIONARY FILE UPDATES: 3 APR 2007 HIGHEST RN 929074-02-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH DECEMBER 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s sumatriptan succinate/cn
 L10 1 SUMATRIPTAN SUCCINATE/CN

=> d l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS ON STN
 RN 103628-46-4 REGISTRY
 ED Entered STN: 09 Aug 1986
 CN Butanedioic acid, compd. with 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide (1:1) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1) (9CI)

OTHER NAMES:
 CN GR 43175C
 CN Imigran

=> d ibib abs 106

L11 ANSWER 106 OF 106 USPAT2 on STN
ACCESSION NUMBER: 2002:12064 USPAT2 Full-text
TITLE: Rapid-melt semi-solid compositions, methods of making same and methods of using same
INVENTOR(S): Cherukuri, Subraman Rao, Vienna, VA, United States
PATENT ASSIGNEE(S): Capricorn Pharma, Inc., Frederick, MD, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6589556 B2 20030708
APPLICATION INFO.: US 2001-859885 20010517 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-610489, filed on 5 Jul 2000, now patented, Pat. No. US 6375982
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spear, James M.
ASSISTANT EXAMINER: Fuhara, Blessing
LEGAL REPRESENTATIVE: Nath & Associates PLLC, Nath, Gary M., Meyer, Jerald L.
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel rapid-melt, semi-solid molded composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal wherein the prophylactic or therapeutic active is a psychotropic, a gastrointestinal therapeutic or a migraine therapeutic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 105

L11 ANSWER 105 OF 106 USPAT2 on STN
ACCESSION NUMBER: 2002:78243 USPAT2 Full-text
TITLE: Porous pacitaxel matrices and methods of manufacture thereof
INVENTOR(S): Straub, Julie, Winchester, MA, United States
Bernstein, Howard, Cambridge, MA, United States
Chickering, III, Donald E., Framingham, MA, United States
Khattak, Sarwat, Amherst, MA, United States
Randall, Greg, Somerville, MA, United States
Acusphere, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6610317 B2 20030826
APPLICATION INFO.: US 2001-798824 20010302 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-US14578, filed on 25 May 2000

NUMBER DATE

PRIORITY INFORMATION: US 2000-186310P 20000302 (60)
US 1999-158659P 19991008 (60)
US 1999-136323P 19990527 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Dewitty, Robert M
LEGAL REPRESENTATIVE: Holland & Knight LLP

NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 775

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pacitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The pacitaxel matrices preferably are made using a process that includes (i) dissolving pacitaxel in a volatile solvent to form a pacitaxel solution, (ii) combining at least one pore forming agent with the pacitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of pacitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the pacitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous pacitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l11 and sumatriptan/clm
L12 51 L11 AND SUMATRIPTAN/CLM

=> d ibib abs 51

L12 ANSWER 51 OF 51 USPAT2 on STN
ACCESSION NUMBER: 2002:12064 USPAT2 Full-text
TITLE: Rapid-melt semi-solid compositions, methods of making same and methods of using same
INVENTOR(S): Cherukuri, Subraman Rao, Vienna, VA, United States
PATENT ASSIGNEE(S): Capricorn Pharma, Inc., Frederick, MD, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6589556 B2 20030708
APPLICATION INFO.: US 2001-859885 20010517 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-610489, filed on 5 Jul 2000, now patented, Pat. No. US 6375982

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spear, James M.
ASSISTANT EXAMINER: Fuhara, Blessing
LEGAL REPRESENTATIVE: Nath & Associates PLLC, Nath, Gary M., Meyer, Jerald L.
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel rapid-melt, semi-solid molded composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal wherein the prophylactic or therapeutic active is a psychotropic, a gastrointestinal therapeutic or a migraine therapeutic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 50

L12 ANSWER 50 OF 51 USPAT2 on STN
ACCESSION NUMBER: 2004:158099 USPAT2 Full-text
TITLE: Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally optional flavoring agent; and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, and optional flavoring agent, and propellant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l12 and sumatriptan/ab
L13 10 L12 AND SUMATRIPTAN/AB

=> d ibib abs tot

L13 ANSWER 1 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006-274081 USPATFULL Full-text
TITLE: Taste masked sumatriptan tablets and processes for their preparation

INVENTOR(S):
Kumar, T. Vijaya, Andhra Pradesh, INDIA
Roy, Sunilendu Bhushan, Maharashtra, INDIA
Malik, Rajiv, Wein, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006233875	A1	20061019
APPLICATION INFO.:	US 2003-521402	A1	20030717 (10)
	WO 2003-1B2838		20030717
			20060301 PCT 371 date

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 49

L12 ANSWER 49 OF 51 USPAT2 on STN
ACCESSION NUMBER: 2004-158100 USPAT2 Full-text
TITLE: Buccal, polar and non-polar spray or capsule containing drugs for treating pain

INVENTOR(S):
Dugger, III, Harry A., Flemington, NJ, UNITED STATES
PATENT ASSIGNEE(S): Novadel Pharma, Inc., Flemington, NJ, UNITED STATES (U.S. corporation)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006-196517 USPATFULL Full-text
TITLE: Amorphous (sumatriptan) succinate
INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, INDIA
Murthy, Mokkara Surya Narayana, Hyderabad, INDIA
Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006167274	A1	20060727
APPLICATION INFO.:	US 2006-386608	A1	20060322 (11)
RELATED APPLN. INFO.:			Continuation of Ser. No. US 2003-627399, filed on 25 Jul 2003, GRANTED, Pat. No. US 7034162

INVENTOR(S): Dugger, III, Harry A., Flemington, NJ, UNITED STATES
PATENT ASSIGNEE(S): Novadel Pharma, Inc., Flemington, NJ, UNITED STATES (U.S. corporation)

PATENT INFORMATION: US 6977070 B2 20051220
APPLICATION INFO.: US 2003-726585 20031204 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2002-230060, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-537118, filed on 29 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary
ASSISTANT EXAMINER: Haghighatian, Mina
LEGAL REPRESENTATIVE: Dickstein Shapiro Morin & Oshinsky LLP
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 986

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally optional flavoring agent; and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, and optional flavoring agent, and propellant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 49

L12 ANSWER 49 OF 51 USPAT2 on STN
ACCESSION NUMBER: 2004-158100 USPAT2 Full-text
TITLE: Buccal, polar and non-polar spray or capsule containing drugs for treating pain

INVENTOR(S):
Dugger, III, Harry A., Flemington, NJ, UNITED STATES
PATENT ASSIGNEE(S): Novadel Pharma, Inc., Flemington, NJ, UNITED STATES (U.S. corporation)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation.

L13 ANSWER 2 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006-196517 USPATFULL Full-text
TITLE: Amorphous (sumatriptan) succinate
INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, INDIA
Murthy, Mokkara Surya Narayana, Hyderabad, INDIA
Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

other antimigraine drugs for the treatment of migraine
RUDOLF, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
DOODS, Henri, Warthausen, GERMANY, FEDERAL REPUBLIC OF
MUELLER, Stephan Georg, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ZAMPONI, Annette, Biberach, GERMANY, FEDERAL REPUBLIC
OF
LUSTENBERGER, Philipp, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ARNDT, Kirsten, Biberach, GERMANY, FEDERAL REPUBLIC OF
SCHAENZLE, Gerhard, Biberach-Mettenberg, GERMANY,
FEDERAL REPUBLIC OF
STENKAMP, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Brickl, Rolf-Stefan, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT ASSIGNEE(S):
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006142273 A1 20060629
US 2005-275169 A1 20051216 (11)

PATENT INFORMATION:
DOCUMENT TYPE:
UTILITY
FILE SEGMENT:
APPLICATION
LEGAL REPRESENTATIVE:
MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
11
1
LINE COUNT:
1477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a process for the treatment or prevention of indications
which are selected from among the group comprising headaches, migraine and cluster
headaches, this process comprising the joint administration of a therapeutically
effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt
thereof or a hydrate of the salt and a therapeutically effective amount of a second or
third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or
dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding
pharmaceutical compositions and the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L13 ANSWER 5 OF 10 USPATFULL ON STN
ACCESSION NUMBER:
2006:125492 USPATFULL Full-text
TITLE:
3'-2-(Dimethylamino) ethyl-1-n-methyl-1h-indole-5-
methanesulfonamide and the succinate thereof
INVENTOR(S):
Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED
STATES
Murthy, Mokkara Suryanarayana, Hyderabad, IN, UNITED
STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED
STATES
Dr Reddy's Laboratories Limited, Hyderabad 500 016,
Andhra Pradesh, INDIA (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006106227 A1 20060518
US 2004-516897 A1 20040616 (10)
WO 2004-US19004
20050705 PCT 371 date

INVENTOR(S):
RUDOLF, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
DOODS, Henri, Warthausen, GERMANY, FEDERAL REPUBLIC OF
MUELLER, Stephan Georg, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ZAMPONI, Annette, Biberach, GERMANY, FEDERAL REPUBLIC
OF
LUSTENBERGER, Philipp, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ARNDT, Kirsten, Biberach, GERMANY, FEDERAL REPUBLIC OF
SCHAENZLE, Gerhard, Biberach-Mettenberg, GERMANY,
FEDERAL REPUBLIC OF
STENKAMP, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Brickl, Rolf-Stefan, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT ASSIGNEE(S):
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006142273 A1 20060629
US 2005-275169 A1 20051216 (11)

PATENT INFORMATION:
DOCUMENT TYPE:
UTILITY
FILE SEGMENT:
APPLICATION
LEGAL REPRESENTATIVE:
MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
11
1
LINE COUNT:
1477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a process for the treatment or prevention of indications
which are selected from among the group comprising headaches, migraine and cluster
headaches, this process comprising the joint administration of a therapeutically
effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt
thereof or a hydrate of the salt and a therapeutically effective amount of a second or
third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or
dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding
pharmaceutical compositions and the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L13 ANSWER 5 OF 10 USPATFULL ON STN
ACCESSION NUMBER:
2006:125492 USPATFULL Full-text
TITLE:
3'-2-(Dimethylamino) ethyl-1-n-methyl-1h-indole-5-
methanesulfonamide and the succinate thereof
INVENTOR(S):
Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED
STATES
Murthy, Mokkara Suryanarayana, Hyderabad, IN, UNITED
STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED
STATES
Dr Reddy's Laboratories Limited, Hyderabad 500 016,
Andhra Pradesh, INDIA (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006106227 A1 20060518
US 2004-516897 A1 20040616 (10)
WO 2004-US19004
20050705 PCT 371 date

other antimigraine drugs for the treatment of migraine
RUDOLF, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
DOODS, Henri, Warthausen, GERMANY, FEDERAL REPUBLIC OF
MUELLER, Stephan Georg, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ZAMPONI, Annette, Biberach, GERMANY, FEDERAL REPUBLIC
OF
LUSTENBERGER, Philipp, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ARNDT, Kirsten, Biberach, GERMANY, FEDERAL REPUBLIC OF
SCHAENZLE, Gerhard, Biberach-Mettenberg, GERMANY,
FEDERAL REPUBLIC OF
STENKAMP, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Brickl, Rolf-Stefan, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT ASSIGNEE(S):
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006142273 A1 20060629
US 2005-275169 A1 20051216 (11)

PATENT INFORMATION:
DOCUMENT TYPE:
UTILITY
FILE SEGMENT:
APPLICATION
LEGAL REPRESENTATIVE:
MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
11
1
LINE COUNT:
1477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a process for the treatment or prevention of indications
which are selected from among the group comprising headaches, migraine and cluster
headaches, this process comprising the joint administration of a therapeutically
effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt
thereof or a hydrate of the salt and a therapeutically effective amount of a second or
third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or
dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding
pharmaceutical compositions and the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L13 ANSWER 5 OF 10 USPATFULL ON STN
ACCESSION NUMBER:
2006:125492 USPATFULL Full-text
TITLE:
3'-2-(Dimethylamino) ethyl-1-n-methyl-1h-indole-5-
methanesulfonamide and the succinate thereof
INVENTOR(S):
Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED
STATES
Murthy, Mokkara Suryanarayana, Hyderabad, IN, UNITED
STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED
STATES
Dr Reddy's Laboratories Limited, Hyderabad 500 016,
Andhra Pradesh, INDIA (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006106227 A1 20060518
US 2004-516897 A1 20040616 (10)
WO 2004-US19004
20050705 PCT 371 date

other antimigraine drugs for the treatment of migraine
RUDOLF, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
DOODS, Henri, Warthausen, GERMANY, FEDERAL REPUBLIC OF
MUELLER, Stephan Georg, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ZAMPONI, Annette, Biberach, GERMANY, FEDERAL REPUBLIC
OF
LUSTENBERGER, Philipp, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ARNDT, Kirsten, Biberach, GERMANY, FEDERAL REPUBLIC OF
SCHAENZLE, Gerhard, Biberach-Mettenberg, GERMANY,
FEDERAL REPUBLIC OF
STENKAMP, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Brickl, Rolf-Stefan, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT ASSIGNEE(S):
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006142273 A1 20060629
US 2005-275169 A1 20051216 (11)

PATENT INFORMATION:
DOCUMENT TYPE:
UTILITY
FILE SEGMENT:
APPLICATION
LEGAL REPRESENTATIVE:
MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
11
1
LINE COUNT:
1477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a process for the treatment or prevention of indications
which are selected from among the group comprising headaches, migraine and cluster
headaches, this process comprising the joint administration of a therapeutically
effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt
thereof or a hydrate of the salt and a therapeutically effective amount of a second or
third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or
dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding
pharmaceutical compositions and the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L13 ANSWER 5 OF 10 USPATFULL ON STN
ACCESSION NUMBER:
2006:125492 USPATFULL Full-text
TITLE:
3'-2-(Dimethylamino) ethyl-1-n-methyl-1h-indole-5-
methanesulfonamide and the succinate thereof
INVENTOR(S):
Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED
STATES
Murthy, Mokkara Suryanarayana, Hyderabad, IN, UNITED
STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED
STATES
Dr Reddy's Laboratories Limited, Hyderabad 500 016,
Andhra Pradesh, INDIA (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006106227 A1 20060518
US 2004-516897 A1 20040616 (10)
WO 2004-US19004
20050705 PCT 371 date

other antimigraine drugs for the treatment of migraine
RUDOLF, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
DOODS, Henri, Warthausen, GERMANY, FEDERAL REPUBLIC OF
MUELLER, Stephan Georg, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ZAMPONI, Annette, Biberach, GERMANY, FEDERAL REPUBLIC
OF
LUSTENBERGER, Philipp, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ARNDT, Kirsten, Biberach, GERMANY, FEDERAL REPUBLIC OF
SCHAENZLE, Gerhard, Biberach-Mettenberg, GERMANY,
FEDERAL REPUBLIC OF
STENKAMP, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Brickl, Rolf-Stefan, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT ASSIGNEE(S):
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006142273 A1 20060629
US 2005-275169 A1 20051216 (11)

PATENT INFORMATION:
DOCUMENT TYPE:
UTILITY
FILE SEGMENT:
APPLICATION
LEGAL REPRESENTATIVE:
MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
11
1
LINE COUNT:
1477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a process for the treatment or prevention of indications
which are selected from among the group comprising headaches, migraine and cluster
headaches, this process comprising the joint administration of a therapeutically
effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt
thereof or a hydrate of the salt and a therapeutically effective amount of a second or
third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or
dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding
pharmaceutical compositions and the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L13 ANSWER 5 OF 10 USPATFULL ON STN
ACCESSION NUMBER:
2006:125492 USPATFULL Full-text
TITLE:
3'-2-(Dimethylamino) ethyl-1-n-methyl-1h-indole-5-
methanesulfonamide and the succinate thereof
INVENTOR(S):
Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED
STATES
Murthy, Mokkara Suryanarayana, Hyderabad, IN, UNITED
STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED
STATES
Dr Reddy's Laboratories Limited, Hyderabad 500 016,
Andhra Pradesh, INDIA (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006106227 A1 20060518
US 2004-516897 A1 20040616 (10)
WO 2004-US19004
20050705 PCT 371 date

PRIORITY INFORMATION: GB 2003-17904 20030731
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Daniel F. Coughlin, Esq., Mintz Levin Cohn Ferris
Glovsky and Popeo PC, Chrysler Center, 666 Third
Avenue, New York, NY, 10017
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: CLM-001-9
LINE COUNT: 618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is concerned with a unit dosage form containing sumatriptan and metoclopramide. The unit dosage form is so configured that a portion of the sumatriptan dose is provided in a first phase adapted for immediate release of sumatriptan, and a second portion is contained in a second phase adapted for the sustained release of sumatriptan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:185116 USPATFULL Full-text
TITLE: Amorphous form of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methane sulfonamide succinate (sumatriptan succinate)
INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Murthy, Srinivasan Thirumalai, Hyderabad, INDIA
Murthy, Mokkara Surya Narayana, Hyderabad, INDIA
Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA
PATENT ASSIGNEE(S): DR. REDDY'S LABORATORIES LIMITED (non-U.S. corporation)
DR. REDDY'S LABORATORIES, INC. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004:143002	A1	20040722
APPLICATION INFO.:	US 7034162	B2	20060425
	US 2003-627399	A1	20030725 (10)

PRIORITY INFORMATION: IN 2002-5942002 20020812
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an amorphous form of Sumatriptan succinate of Formula (1). The present invention also relates to process for the preparation of an amorphous form of Sumatriptan succinate. The process for the preparation of an amorphous form of Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrile solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:177749 USPATFULL Full-text
TITLE: Buccal, polar and non-polar spray containing sumatriptan
INVENTOR(S): Dugger, Harry A., III, Flemington, NJ, UNITED STATES
Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES

PRIORITY INFORMATION: IN 2002-45102 20020613
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DR. REDDY'S LABORATORIES, INC., 200 SOMERSET CORPORATE
BLVD, SEVENTH FLOOR,, BRIDGEWATER, NJ, 08807-2862, US
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 672
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the preparation of highly pure Sumatriptan is described. A process for the preparation of novel crystalline Form I and crystalline Form II of Sumatriptan succinate is described. Sumatriptan is used for alleviating the pain of migraine headaches.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006:3533 USPATFULL Full-text
TITLE: Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
INVENTOR(S): Ahmed, Salah U., New City, NY, UNITED STATES
Li, Lianli, Pomona, NY, UNITED STATES
Naini, Venkatesh, Parsippany, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006002989	A1	20060105
APPLICATION INFO.:	US 2005-149444	A1	20050610 (11)

PRIORITY INFORMATION: US 2004-578286P 20040610 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERN, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK
AVENUE, N.W., WASHINGTON, DC, 20005, US
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 973
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to pharmaceutical compositions comprising sumatriptan succinate and sodium caprate for increased absorption of sumatriptan succinate across biological membranes. The invention is also directed to methods of making the pharmaceutical compositions and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2005:38196 USPATFULL Full-text
TITLE: Pharmaceutical compositions comprising sumatriptan and metoclopramide, and methods of use thereof
INVENTOR(S): Vergnault, Guy, Lechle, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005032876	A1	20050210
APPLICATION INFO.:	US 2004-888324	A1	20040709 (10)

form of Sumatriptan succinate. The process for the preparation of an amorphous form of Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrile solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>
=>
=> log hold
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY
TOTAL SESSION
130.00
187.55

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:26:25 ON 04 APR 2007

AB Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II: aqueous polar solvent, sumatriptan, optionally flavoring agent, and propellant; formulation III: non-polar solvent, sumatriptan, and optional flavoring agent; formulation IV: non-polar solvent, sumatriptan, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, sumatriptan, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, sumatriptan, optional flavoring agent, and propellant.

PATENT INFORMATION:
APPLICATION INFO.:
RELATED APPLN. INFO.:
US 2004136913 A1 20040715
US 2003-671710 A1 20030929 (10)
Continuation-in-part of Ser. No. US 2002-230059, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-537118, filed on 29 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING
UTILITY
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM:
NUMBER OF DRAWINGS: 1
LINE COUNT: 1
1 Drawing Page(s)
1167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 10 USPAT2 on STN
ACCESSION NUMBER: 2004:185116 USPAT2 Full-text
TITLE: Amorphous form of 3-(2-(dimethylamino) ethyl)-N-methyl-1H-indole-5-methane sulfonamide succinate (sumatriptan succinate)
INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, INDIA
Murthy, Mokkara Suvvanarayana, Hyderabad, INDIA
Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA
Dr. Reddy's Laboratories Limited, Hyderabad, INDIA (non-U.S. corporation)
Dr. Reddy's Laboratories, Inc., Upper Saddle River, NJ, UNITED STATES (U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 7034162 B2 20060425
US 2003-627399 20030725 (10)

PATENT INFORMATION:
DOCUMENT TYPE: IN 2000-5942002 20000812
UTILITY
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Solola, Taofiq
ASSISTANT EXAMINER: Shiao, Robert
LEGAL REPRESENTATIVE: Franks, Robert A., Cepeda, Milagros A., Pergament, Edward D.

NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1
LINE COUNT: 1
1 Drawing Figure(s); 1 Drawing Page(s)
266

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an amorphous form of Sumatriptan succinate of Formula (1). The present invention also relates to process for the preparation of an amorphous